- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.07. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference | 207 | ACCESS Newswire | - Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in... ► Artikel lesen | |
| 22.07. | XFRA BE50: AUSSETZUNG/SUSPENSION | 193 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCNS PHARM.INC.NEW... ► Artikel lesen | |
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 22.07. | XFRA NEW INSTRUMENTS AVAILABLE ON 22.07.2025 | 395 | Xetra Newsboard | The following instruments on XETRA do have their first trading 22.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 22.07.2025
Aktien
1 NGGTCO000002 Guaranty Trust Holding... ► Artikel lesen | |
| 21.07. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.07.2025 | 307 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 21.07.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.07.2025ISIN NameCA7703631092 ROBERTO... ► Artikel lesen | |
| 21.07. | XFRA ISIN CHANGE | 276 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS18978H4092 CNS Pharmaceuticals Inc. 21.07.2025 US18978H5081 CNS Pharmaceuticals Inc. 22.07.2025 Tausch 12:1CA86218J2048 Storm... ► Artikel lesen | |
| 18.07. | CNS Pharmaceuticals announces 1-for-12 reverse stock split | 4 | Investing.com | ||
| 18.07. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Reverse Stock Split | 210 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for... ► Artikel lesen | |
| 15.07. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.07. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment | 364 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
| 24.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme and Lead Product Candidate TPI 287 | 202 | ACCESS Newswire | Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS... ► Artikel lesen | |
| 05.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | 292 | ACCESS Newswire | In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire... ► Artikel lesen | |
| 16.05. | CNS Pharmaceuticals reports Q1 results | 4 | Seeking Alpha | ||
| 16.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | 401 | ACCESS Newswire | Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme... ► Artikel lesen | |
| 15.05. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | CNS Pharmaceuticals Stock Surges 36% On $5 Mln Public Offering Announcement | 1 | RTTNews | ||
| 13.05. | CNS Pharmaceuticals sets terms for $5 million stock offering | 3 | Investing.com | ||
| 13.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | 687 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
| 13.05. | Pre-market Movers: Lobo EV Technologies, CNS Pharmaceuticals, Landsea Homes, Inno Holdings, Lichen International | 601 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.25 A.M. ET).In the Green Lobo EV Technologies Ltd. (LOBO) is up over 160%... ► Artikel lesen | |
| 13.05. | CNS Pharmaceuticals erhält Orphan-Drug-Status für Krebsmedikament | 7 | Investing.com Deutsch | ||
| 13.05. | CNS Pharmaceuticals secures orphan drug status for cancer drug | 2 | Investing.com |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,748 | +0,42 % | CureVac ÜBERRASCHT Anleger: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
| PALATIN TECHNOLOGIES | 0,300 | 0,00 % | Aktionäre von Palatin Technologies stimmen Reverse-Aktiensplit und Vorstandswahlen zu | ||
| BIOXXMED | 0,420 | -2,33 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, INC. - 10-K/A, Annual Report | ||
| OCUGEN | 0,923 | -0,97 % | Ocugen, Inc. - 8-K, Current Report | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 0,985 | -4,37 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,387 | +0,26 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,317 | +1,15 % | Vaxart, Inc.: Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq | - Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,840 | +1,66 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 First Quarter Conference Call and Presentation to Be Held on August 13, 2025 | Vancouver, British Columbia--(Newsfile Corp. - July 30, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,800 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | Pre-market Movers: DURECT Corporation, Salarius Pharmaceuticals, ScanTech AI Systems, AIM ImmunoTech, Bakkt Holdings | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.25 A.M. ET).In the Green DURECT Corporation (DRRX) is up over 267% at $2.03.
Salarius... ► Artikel lesen | |
| IMMUNIC | 0,847 | -0,35 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,132 | +159,84 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen |
CNS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 7,710 Euro und damit -3,50 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.